Related Experiment Videos
Alpha-Monofluoromethyldopa (MFMD) in combination with L-DOPA Effects on tissue catecholamines and blood pressure in
Abstract:
We have investigated the interaction of alpha-monofluoromethyldopa (MFMD) with the effects of i.p. injected L-DOPA (200 mg.kg-1) on blood pressure and tissue catecholamines in normal and spontaneously hypertensive rats (SHR). MFMD 10 mg.kg-1 (i.p.) effectively antagonizes the L-DOPA induced increase in heart dopamine (DA). This action is also seen after 15 or 50 mg.kg-1. The accumulation of DA in the brain is very much reduced by MFMD 50 mg.kg-1 while after 15 or, especially, 10 mg.kg-1 more DA is formed in the brain than after L-DOPA alone, probably due to the peripheral decarboxylase inhibition which presents more L-DOPA to the brain. We conclude that MFMD 10 mg.kg-1 gives a relatively selective peripheral inhibition of the decarboxylation of L-DOPA and this dose combination was accordingly found to result in a reduction of blood pressure in conscious animals. This hypotensive response to L-DOPA was attenuated after MFMD 15 mg.kg-1 and was absent after MFMD 50 mg.kg-1. Interestingly, the hypotensive effect of L-DOPA after MFMD 10 or 15 mg.kg-1 was more pronounced in SHR.
Insights
Alpha-monofluoromethyldopa (MFMD) selectively inhibits peripheral L-DOPA metabolism, reducing blood pressure in rats. This interaction is more pronounced in spontaneously hypertensive rats, suggesting therapeutic potential.
Area of Science:
- Pharmacology
- Neuroscience
- Cardiovascular Research
Background:
- Levodopa (L-DOPA) is a primary treatment for Parkinson's disease.
- Peripheral L-DOPA metabolism affects its central efficacy and side effects.
- Alpha-monofluoromethyldopa (MFMD) is a decarboxylase inhibitor with potential to modulate L-DOPA's effects.
Purpose of the Study:
- To investigate the interaction between MFMD and L-DOPA on blood pressure and catecholamine levels.
- To determine the selectivity of MFMD's peripheral decarboxylase inhibition.
- To assess the effects in both normal and spontaneously hypertensive rats (SHR).
Main Methods:
- Rats (normal and SHR) received intraperitoneal injections of L-DOPA (200 mg/kg).
- Varying doses of MFMD (10, 15, 50 mg/kg) were co-administered.
- Blood pressure and tissue catecholamine levels (including dopamine) were measured.
Main Results:
- MFMD (10 mg/kg) selectively inhibited heart dopamine increase induced by L-DOPA.
- Higher MFMD doses (15, 50 mg/kg) reduced brain dopamine accumulation.
- MFMD (10 mg/kg) combined with L-DOPA lowered blood pressure, an effect attenuated by higher MFMD doses.
- The hypotensive effect was more pronounced in SHR.
Conclusions:
- MFMD at 10 mg/kg selectively inhibits peripheral L-DOPA decarboxylation.
- This selective inhibition leads to a hypotensive response, particularly in SHR.
- MFMD dosage is critical for achieving selective peripheral inhibition and desired cardiovascular effects.